Form 4 for DMAA Drugs Made In America Acquisition Corp.
Accepted 2025-02-04 00:00:00 ET · period of report 2025-01-29 · accession 0001213900-25-010195 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-04 | 2025-01-29 | DMAA | Drugs Made In America Acquisition LLC | 10% | P - Purchase | — | +400.0K | 10.26M | +4% | — |
| D | 2025-02-04 | 2025-01-29 | DMAA | Drugs Made In America Acquisition LLC | 10% | S - Sale | — | -5.70M | 4.16M | -58% | — |
| D | 2025-02-04 | 2025-01-29 | DMAA | Drugs Made In America Acquisition LLC | 10% | J - Other | — | -400.0K | 9.86M | -4% | — |
| D | 2025-02-04 | 2025-01-29 | DMAA | Drugs Made In America Acquisition LLC | 10% | P - Purchase | — | +400.0K | 400.0K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary shares | 2025-01-29 | P | A | 400,000 | — | 10,257,143 | D | — | — | (F1) Reflects the 400,000 private units owned by the reporting person, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $4,000,000. |
| 2 | Common | Ordinary shares | 2025-01-29 | S | D | 5,698,363 | — | 4,158,780 | D | — | — | (F3) As of the Transaction Date, pursuant to share transfer agreements, the reporting person transferred an aggregate of 5,698,363 ordinary shares for consideration ranging from no consideration to $1.50 per share. |
| 3 | Common | Ordinary shares | 2025-01-29 | J | D | 400,000 | — | 9,857,143 | D | — | — | (F2) As of the Transaction Date, the reporting person transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration. |
| 4 | Derivative | Rights to receive ordinary shares | 2025-01-29 | P | A | 400,000 | — | 400,000 | D | — · — to — | 400,000 Ordinary shares | (F1) Reflects the 400,000 private units owned by the reporting person, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $4,000,000. (F4) The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination. |